pharma · Multiple Sclerosis · Relapsing Remitting Multiple Sclerosis · CTNM
Contineum Therapeutics
Contineum Therapeutics clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- San Diego, USA
- Founded
- 2017
- Employees
- 59
- Programs
- 7
- Drugs
- 3
- Patents
- 2
Contineum Therapeutics projects
7 ClinicalTrials.gov programs sponsored by Contineum Therapeutics.
Contineum Therapeutics has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
PIPE-307 Dose A
Contineum Therapeutics
Relapsing Remitting Multiple Sclerosis
1 trial -
PIPE-505
Contineum Therapeutics
Sensorineural Hearing Loss
1 trial -
PIPE-791 Dose A
Contineum Therapeutics
Idiopathic Pulmonary Fibrosis
1 trial -
PIPE-307
Contineum Therapeutics
Multiple Sclerosis
2 trials -
PIPE-791
Contineum Therapeutics
Chronic Osteoarthritis Pain
1 trial -
PIPE-791
Contineum Therapeutics
Idiopathic Pulmonary Fibrosis (IPF)
1 trial -
PIPE-791
Contineum Therapeutics
Multiple Sclerosis
1 trial
Frequently asked questions
How many clinical projects does Contineum Therapeutics have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.